Skip to main content
SpringerLink
Log in

High Molecular Weight Forms of Deferoxamine: Novel Therapeutic Agents for Treatment of Iron-Mediated Tissue Injury

  • Chapter
Book cover Antioxidants in Therapy and Preventive Medicine

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 264))

Abstract

The iron chelator, deferoxamine (Desferal®), is presently used clinically for the treatment of acute and chronic iron toxicity. The chelator is an effective inhibitor of iron-catalyzed reactions leading to the formation of both oxygen and lipid-derived radicals. Deferoxamine (DFO) has been incorporated in a number of studies involving oxygen and lipid radical mediated reactions leading to tissue injury and has proven efficacious in ameliorating reperfusion injury.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. A. Mazur, S. Baez, and E. Shorr, The mechanism of iron release from ferritin as related to its biological properties, J. Biol. Chem. 213:147 (1955).

    PubMed  CAS  Google Scholar 

  2. C. E. Thomas, L. A. Morehouse, and S. D. Aust, Ferritin and superoxide-dependent lipid peroxidation, J. Biol. Chem. 260:3275 (1985).

    PubMed  CAS  Google Scholar 

  3. P. Biemond, A. J. G. Swaak, C. M. Biendorff, and J. F. Koster, Superoxide-dependent and independent mechanisms of iron mobilization from ferritin by xanthine oxidase, Biochem. J. 239:169 (1986).

    PubMed  CAS  Google Scholar 

  4. M. S. Paller, and B. E. Hedlund, Role of iron in postischemic renal injury in the rat,KidneyInt. 34:474 (1980).

    Article  Google Scholar 

  5. G. Ambrosio, J. L. Zweier, W. E. Jacobus, M. L. Weisfeldt, and J. T. Flaherty, Improvement of postischemic myocardial function and metabolism induced by administration of defer oxamine at the time of reflow: The role of iron in the pathogenesis of reperfusion injury, Circulation 76:906 (1987).

    Article  PubMed  CAS  Google Scholar 

  6. S. F. Badylak, A. Simmons, J. Turek, and C. F. Babbs, Protection from reperfusion injury in the isolated rat heart by postischemic deferoxamine and allopurinol administration, Cardiovasc. Res. 21:500 (1987).

    Article  PubMed  CAS  Google Scholar 

  7. R. Bolli, B. S. Patel, W. X. Zhu, P. G. ONeill, M. L. Charlat, and R. Roberts, The iron chelator deferoxamine attenuates postischemic ventricular dysfunction, Am. J., Physiol. 253: H1372-H1380 (1987).

    Google Scholar 

  8. N. E. Farber, G. M. Vercellotti, H. S. Jacob, G. M. Pieper, and G. J. Gross, Evidence for a role of iron in functional and metabolic stunning in the canine heart, Circ. Res. 63:351 (1988).

    PubMed  CAS  Google Scholar 

  9. B. R. Reddy, R. A. Kloner, and K. Przyklenk, Early treatment with deferoxamine limits myocardial ischemia/reperfusion injury, Free Rad. Biol. Med., in press (1989).

    Google Scholar 

  10. C. F. Babbs, The role of iron ions in the genesis of reperfusion injury following successful cardipulmonary resuscitation: Preliminary data and a biochemical hypothesis, Ann. Emerg. Med. 14:777 (1985).

    Article  PubMed  CAS  Google Scholar 

  11. S. Sanan, G. Sharma, R. Malhotra, D. P. Sanan, P. Jain and P. Vadhera: Protection by desferrioxamine against histopathological changes of the liver in the post-oligaemic of clini cal haemomorrhagic shock in dogs: Correlation with improved survival rate and recovery. Free Rad. Res. Commun. 6:29 (1989).

    Article  CAS  Google Scholar 

  12. C. F. Whitten, G. W. Gibson, M. H. Good, J. F. Goodwin, and A. J. Brough, Studies in acute iron poisoning. I. Desferrioxamine in the treatment of acute iron poisoning: Clinical observations, experimental studies, and theoretical considerations, Pediatrics 36:322 (1965).

    CAS  Google Scholar 

  13. C. F. Whitten, Y-C. Chen, and G. W. Gibson, Studies in acute iron poisoning: II. Further observations on desferrioxamine in the treatment of acute experimental iron poisoning, Pediatrics 38:102 (1966).

    PubMed  CAS  Google Scholar 

  14. A. Slivka, J. Kang, and G. Cohen, Hydroxyl radicals and the toxicity of oral iron, Biochem. Pharmacol. 35:553 (1986).

    Article  PubMed  CAS  Google Scholar 

  15. J. O. Kang, A. Slivka, and G. Cohen, In vivo formation of hydroxyl radicals following intragastric administration of ferrous salts in rats, J. Inorg. Biochem. 35:55 (1989).

    Article  PubMed  CAS  Google Scholar 

  16. J. O. Hoppe, G. M. A. Marcelli, and M. L. Tainter, An experimental study of the toxicity of ferrous gluconate, Am. J. Med. Sri. 230:491 (1955).

    Article  CAS  Google Scholar 

  17. P. E. Hallaway, J. W. Eaton, S. S. Panter, and B. E. Hedlund, Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers, Submitted for publication (1989).

    Google Scholar 

  18. T.L. Litovitz, B.F. Schmitz, N. Matyunas and T.G. Martin. 1987 Annual Report of the American Association of Poison Control Centers National Data Collection System. Am. J. Emer. Med. 6:479 (1988).

    Article  CAS  Google Scholar 

  19. C. E. Ganote, and G. Nahara, Acute ferrous sulfate hepatotoxicity in rats. An electron microscopic and biochemical study, Lab. Invest. 28:426 (1973).

    PubMed  CAS  Google Scholar 

  20. E. Graf, J. R. Mahoney, Jr., J. R. Bryant, and J. W. Eaton, Iron-catalyzed hydroxyl radical formation: Stringent requirement for iron-coordinated water, J. Biol. Chem. 295:3620 (1984).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biomedical Frontiers, Inc., Minneapolis, Minnesota, USA

    Bo E. Hedlund & Philip E. Hallaway

  2. University of Minnesota, Minneapolis, Minnesota, USA

    John R. Mahoney

Authors
  1. Bo E. Hedlund
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philip E. Hallaway
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John R. Mahoney
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Centre National de la Recherche Scientifique, University of Paris, Paris, France

    Ingrid Emerit

  2. Dept. of Physiology Anatomy, University of California, Berkeley, Berkeley, California, 94720, USA

    Lester Packer

  3. Institut Gustave-Roussy, 94800, Villejuif, France

    Christian Auclair

  4. Groupe de Recherche Radicaux Libres, Institut Biomédical des Cordeliers, 15, Rue de l’Ecole de Médecine, 75006, Paris, France

    Ingrid Emerit

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Plenum Press, New York

About this chapter

Cite this chapter

Hedlund, B.E., Hallaway, P.E., Mahoney, J.R. (1990). High Molecular Weight Forms of Deferoxamine: Novel Therapeutic Agents for Treatment of Iron-Mediated Tissue Injury. In: Emerit, I., Packer, L., Auclair, C. (eds) Antioxidants in Therapy and Preventive Medicine. Advances in Experimental Medicine and Biology, vol 264. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5730-8_37

Download citation

  • DOI: https://doi.org/10.1007/978-1-4684-5730-8_37

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4684-5732-2

  • Online ISBN: 978-1-4684-5730-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation